Related Experiment Videos
The syndrome associated with the withdrawal of beta-adrenergic receptor blocking drugs
British Journal of Clinical Pharmacology
|January 1, 1982
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Long-term treatment of hypertension with labetalol.
British journal of clinical pharmacology·2015
Beta-adrenergic blocking drugs in the treatment of hypertension.
Blood pressure·2002
New approaches to the uses of beta blocking drugs in hypertension.
Journal of human hypertension·2000
Moxonidine: a new antiadrenergic antihypertensive agent.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension·1999
Systematic review of clinical trials and cohort studies evaluating HIV post-exposure prophylaxis (PEP) regimens to inform updated Canadian guidelines.
British journal of clinical pharmacology·2026
Electronic prescribing: Implementation of a new approach to undergraduate teaching and assessment.
British journal of clinical pharmacology·2026
Patient preferences for medicines information in cardiovascular disease and the influence of unmet needs on medication adherence: A cross-sectional study.
British journal of clinical pharmacology·2026
Triangulation of dispensing and wastewater data for surveillance during lisdexamfetamine shortages: A descriptive time series analysis.
British journal of clinical pharmacology·2026
Practice-level variation in potentially inappropriate prescribing in middle-aged adults: A repeated cross-sectional study in South London general practice.
British journal of clinical pharmacology·2026
Current perspectives in the pharmacological management of cutaneous and mucosal leishmaniasis.
Expert opinion on pharmacotherapy·2026
New potassium binders: we need them-we do not need them.
Clinical kidney journal·2026
Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity.
Diabetes, obesity, and cardiometabolic CARE·2026
Ibogaine for Substance Use Disorders.
Advances in therapy·2026